3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

INSIDE INFORMATION
CHANGE IN USE OF PROCEEDS FROM 2023 PLACING

This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on the Stock Exchange and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "**SFO**"). References are made to the announcements of 3D Medicines Inc. (the "**Company**", together with its subsidiaries, the "**Group**") dated July 14, 2023 and July 21, 2023 (the "**Announcements**") and the interim report of the Company for the six months ended June 30, 2024 (the "**2024 Interim Report**"). Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the Announcements and the 2024 Interim Report.

This announcement is made to provide an update of the use of proceeds from the placing of 2,150,000 new shares issued at a price of HK$108.00 per share, which was completed on July 21, 2023 (the "**Placing**").

CHANGE IN USE OF PROCEEDS

For the reasons stated in the paragraphs under the heading "Reasons for and Benefits of the Change in Use of Proceeds" below, the board of directors of the Company (the "**Board**") has resolved to change the use of the net proceeds from the Placing (the **"Net Proceeds**"), which amounted to approximately RMB183.50 million as at the date of this announcement (the "**Unutilised Net Proceeds"**). The change involves reallocating part of the funds from the original use on planned clinical trials to evaluate envafolimab monotherapy into a new planned use in the Phase III Trial in NSCLC Perioperative Regimens – KN035-CN-017 ("**NSCLC Perioperative Regimens Trial**"). Set out below is a summary of the utilisation of the Net Proceeds as of the date of this announcement and the proposed change of use of the remaining Unutilised Net Proceeds:

	Total net proceeds from the 2023 Placing *(RMB'000)*	Unutilised amount as at June 30, 2024 *(RMB'000)*	Unutilised amount as at the date of this announcement *(RMB'000)*	Change of allocation of proceeds *(RMB'000)*	Revised allocation of proceeds *(RMB'000)*	Expected time frame for unutilized amounts
Planned clinical trials to evaluate envafolimab monotherapy	103,686.4	101,217.3	100,549.3	(96,000.0)	4,549.3	Dec, 2025
Planned clinical Trial in NSCLC Perioperative Regimens – KN035-CN-017	–	–	–	96,000.0	96,000.0	Dec, 2026
Building construction and procurement of equipment for our manufacturing facilities in Xuzhou, China	82,949.2	82,949.2	82,949.2	–	82,949.2	Dec, 2025
Our general corporate and working capital purposes	20,737.3	–	–	–	–	Not applicable
Total:	**207,372.9**	**184,166.4**	**183,498.4**	**–**	**183,498.4**	

REASONS FOR AND BENEFITS OF THE CHANGE IN USE OF PROCEEDS

As disclosed in the 2024 Interim Report, approximately 50% of the Net Proceeds were originally intended for ongoing and planned clinical trials to evaluate envafolimab monotherapy in subjects with dMMR Advanced Solid Tumors. In view of the smooth progress made in the NSCLC Perioperative Regimens Trial, the Company has reassessed its strategic priorities and allocation of financial resources. The Company believes that reallocating part of the Unutilised Net Proceeds to the NSCLC Perioperative Regimens Trial will better serve its strategic objectives and accelerate the development timetable. The NSCLC Perioperative Regimens Trial aims to evaluate the efficacy and safety of Envafolimab (KN035) in combination with neoadjuvant platinum-based chemotherapy followed by adjuvant Envafolimab monotherapy, compared with a placebo in combination with neoadjuvant platinum-based chemotherapy followed by adjuvant placebo alone, for the treatment of patients with resectable NSCLC. This reallocation aligns with the Company's focus on advancing treatments in areas with significant unmet medical needs, optimizing the use of financial resources, and enhancing the potential for successful clinical and commercial outcomes.

Additionally, the Phase III Trial of the NSCLC Perioperative Regimens Trial is at a more advanced stage of development, providing a clearer regulatory pathway and a higher likelihood of obtaining necessary approvals, thereby reducing the overall risk associated with the clinical development process. The Board is confident that this strategic move will drive significant value for the Company and its stakeholders, ultimately contributing to the advancement of innovative cancer treatments.

The Board will closely monitor the operations of the Group, and the plans for the use of Unutilised Net Proceeds, and may revise or amend such plans where necessary, to cope with the changing market conditions and strive for better business performance of the Group. The Board considers the above change in the use of the Unutilised Net Proceeds is fair and reasonable, as this would allow the Company to deploy its financial resources more effectively to enhance the profitability of the Group and is therefore in the interests of the Group and its shareholders as a whole.

Save as disclosed above, the Board is not aware of any reasons for such price and volume movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under the SFO.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, December 19, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.